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Abstract: The fine-tuning of liver metabolism is essential to maintain the whole-body homeostasis
and to prevent the onset of diseases. The peroxisome proliferator-activated receptor-γ coactivators
(PGC-1s) are transcriptional key players of liver metabolism, able to regulate mitochondrial function,
gluconeogenesis and lipid metabolism. Their activity is accurately modulated by post-translational
modifications. Here, we showed that specific PGC-1s expression can lead to the upregulation of
different microRNAs widely implicated in liver physiology and diseases development and progression,
thus offering a new layer of complexity in the control of hepatic metabolism.
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1. Introduction
Variations of environmental conditions require a constant but flexible adaptation of an organism.
In particular, the rapid changes occurring between fed and fasted state are fulfilled by enzymes
controlling catabolic pathways, while the fast-fed transition is characterized by modulation of anabolic
programs. An efficient fed-fast cycle is of fundamental importance, since failure to induce or inhibit
the expression of metabolic genes has been associated with the development of diseases [1,2]. In the
cell, this is primarily achieved through the activation of a transcriptional machinery that leads to the
expression of genes with different metabolic functions.
The members of the peroxisome proliferator-activated receptor (PPAR)-γ coactivators (PGC-1s)
family are key players in the regulation of energy metabolism. Usually upregulated in conditions
of increased energy demands, these coactivators modulate the expression of several genes involved
in mitochondrial biogenesis and function, as well as in other catabolic and anabolic pathways [3].
The liver is probably the organ that best illustrates the different contributions of the members of the
PGC-1 family to guarantee whole-body homeostasis. Even though many studies have been carried
out considering their specific implication on liver metabolism, several controversies about the specific
functions of different PGC-1 family members still remain.
Another level of regulation in the fed-fast transition is represented by microRNA
(miRNA), small noncoding RNA molecules which control gene expression post-transcriptionally,
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via complementary base pairing with mRNA. These microRNAs are not only able to orchestrate
system-level control over liver physiology and whole-body energetics, but can also contribute to the
pathogenesis of many liver diseases [4,5]. Intriguingly, miRNAs can modulate the activity of PGC-1s,
thus offering a new level of complexity in the regulation of metabolic homeostasis [4]. Conversely,
to our knowledge, little is known about the regulation of miRNAs expression by these coactivators.
The present review discusses some of the new findings regarding the control of PGC-1s expression
and activity as well as the ability of PGC-1s to induce microRNA variously involved in liver physiology
and pathophysiology.
2. Results and Discussion
2.1. The Proliferator-Activated Receptor (PPAR)-γ Coactivator (PGC-1) Family of Transcriptional Coactivators
The PGC-1 family comprises powerful regulators of cellular programs, activated in response
to a plethora of conditions, such as fasting, physical exercise and thermogenesis that collectively
require increased energy demand [3]. PGC-1α is the most well-studied member of this coactivator’s
family, firstly identified as transcriptional coregulator of PPAR-γ in brown adipose tissue [6]. Then,
PGC-1β and PRC (PGC-1 related coactivator) were also recognised, thanks to the extensive sequence
homology and analogous biological functions [7,8]. However, whereas PRC is ubiquitously expressed
in the whole body, PGC-1α and PGC-1β share a similar expression pattern. Indeed, both PGC-1α
and PGC-1β are thoroughly induced in tissues with high oxidative metabolism, like the heart, brown
adipose tissue and type I muscle fibres [9–11]. Still, PRC function has not been well explored, by
contrast with the other two members of the family. In particular, PRC is a growth-regulated cofactor,
with the characteristic of an immediate early gene, i.e., gene expressed early in the cell growth program
as a primary response to multiple stimuli [12]. As expected for a cell growth controller, silencing of PRC
results in a decreased cell proliferation mainly attributable to abnormal mitochondria formation [13].
A critical aspect of PGC-1s is their highly versatile capability to interact with different transcription
factors, activating distinct biological programs in various tissues. PGC-1α was originally described
through its functional interaction with PPARγ in brown adipose tissue (BAT), a mitochondria rich tissue,
where it regulates adaptive thermogenesis [6]. Further studies revealed that the PGC-1s carry out
several biological responses finalized to equip the cell to cope with the alterations of energy demands,
including mitochondrial biogenesis, cellular respiration capacity and substrate uptake and utilization.
The stimulatory effects of PGC-1α on mitochondrial functions are achieved mainly through
its coactivation of nuclear respiratory factors 1 and 2 (NRF1 and NRF2, respectively) and the
estrogen-related receptorα (ERRα) [10,14]. NRFs regulate the expression of mitochondrial transcription
factor A (TFAM), a nuclear-encoded transcription factor essential for replication, maintenance, and
transcription of mitochondrial DNA [15]. NRF1 and NRF2 also control the expression of genes coding
for mitochondrial components of the oxidative phosphorylation apparatus, such as ATP synthase,
cytochrome c, and cytochrome c oxidase [16,17]. Therefore, by stimulating the concomitant expression
of both mitochondrial- and nuclear-encoded proteins, PGC-1α and PGC-1β are able to enhance the
aerobic bioenergetic capacity of the cell, by boosting fatty-acid β-oxidation, Krebs cycle as well as
oxidative phosphorylation.
Besides their well-known role of stimulating mitochondrial biogenesis, PGC-1s also modulate
a variety of other cellular bioenergetic processes, thanks to their interaction and potential binding
to multiple transcription factors [18,19]. This versatility of PGC-1s underlines their pleiotropic
functions involved in the tissue-specific regulation of several metabolic pathways localized in different
cellular compartments.
Although the role of PGC-1α and PGC-1β could sometimes appear to be redundant due to their
overlapping functions, in the liver these coactivators have the ability to regulate distinct processes that
together contribute to hepatic metabolism homeostasis. Indeed, although both coactivators can increase
oxidative metabolism and antioxidant response, PGC-1α plays a major role in catabolic pathways,
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such as gluconeogenesis and fatty acids β-oxidation, by upregulating hepatocyte nuclear factor 4α
(HNF4α), forkhead box protein O1 (FOXO1) and glucocorticoid receptor (GR), while PGC-1β drives
new lipid synthesis and very low density lipoprotein (VLDL) trafficking via coactivation of liver X
receptor (LXR) and sterol regulatory element-binding protein 1c (SREBP1c) [20–25].
Hence, in general conditions of stress, such as food shortage, PGC-1s are upregulated and promote
metabolic programmes aimed to fulfil the energy requirements. Moreover, their ability to sustain
opposite metabolic programmes is essential to prevent futile substrates cycles. Indeed, in a fed status
PGC-1β enhances de novo lipogenesis, while in fasting conditions PGC-1α supports gluconeogenesis.
In this way, both coactivators are entailed in a fine regulation of hepatic glucose availability.
In this view, alterations of PGC-1s pathways can lead to the onset of hepatic diseases, such as
non-alcoholic fatty liver disease (NAFLD), non alcholic steatohepatitis (NASH) and hepatocellular
carcinoma (HCC) [18]. However, despite the large plethora of studies carried out on this topic,
some issues regarding the PGC-1s’ contribution to liver metabolism and diseases need still to
be addressed.
Structure and Regulation
All the members of the PGC-1 family share a similar modular structure, with a strong transcriptional
activation domain at the N-terminus. The C-terminal region of PGC-1s harbours a Ser/Arg rich domain
and an RNA binding domain that couples pre-mRNA splicing with transcription [26]. PGC-1α
and PGC-1β share an additional domain of similarity in the internal region, which roughly spans
200 aminoacids and functions as a repression domain [27].
The PGC-1s interact with several powerful histone acetyl transferase (HAT) complexes at their
N-terminal region, including cAMP response element-binding protein (CREB)-binding protein, p300,
and steroid receptor coactivator-1 (SRC-1) [27]. These proteins acetylate histones and remodel chromatin
structure, thus allowing access of additional factors for transcriptional activation. Other activation
complexes dock at the C-terminus domain: the TRAP/DRIP (thyroid receptor-associated protein/vitamin
D receptor-interacting protein, also known as the Mediator complex) that facilitates direct interaction
with the transcription initiation machinery [28] and the SWI/SNF (switch/sucrose non-fermentable)
that acts as a chromatin-remodelling complex through its interaction with BAF60a [29].
Thus, the remarkably powerful coactivation capacity of PGC-1s may be based on their property to
act as protein docking platforms for the recruitment and assembly of chromatin remodelling and/or
histone-modifying enzymes that facilitate access to DNA for the transcription machinery. Furthermore,
the PGC-1α transcriptional activator complex is also able to displace repressor proteins such as histone
deacetylase and small heterodimer partner (SHP) on its target promoters, providing an alternative
mechanism for an intensified gene transcription [30].
PGC-1α and PGC-1β share similar domains and several clusters of conserved amino acids,
including the LXXLL motif which is recognized by nuclear receptors and host cell factor 1 interacting
motif [7,31].
The mechanism through which the PGC-1s activate gene expression has to date been poorly
understood. Initial studies have identified an extremely powerful autonomous transcriptional activity
at the N-terminal region, due to the ability of PGC-1s to dock two additional coactivators with acetyl
transferase activity on this domain. Similar observations have been made at the C-terminal region
interacting with proteins involved in RNA processing and with the TRAP/DRIP complex involved in
transcriptional initiation. However, how spatially and temporally all these complexes are assembled
to PGC-1s in order to control gene expression is unknown. The major current hypothesis is that
PGC-1s bind to a specific transcription factor at promoter regions, followed by the recruitment of
P300 and TRAP/DRIP complexes which open the chromatin through histone acetylation activity,
thus allowing the initiation of the transcription through RNApolII. Moreover, the presence of several
proteins involved in RNA elongation and processing in the PGC-1s supercomplex suggests that it
might move along the elongating RNA and take part in the mRNA maturation. To terminate gene
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expression, GCN5 (general control of amino acid synthesis), an acetyl transferase, acetylates PGC-1s at
several lysine residues, causing a re-localization of PGC-1s from the promoter region to subnuclear
foci where its transcriptional activity is inhibited [32,33]. By contrast, the enzyme SIRT1 (Sirtuin
1) activates PGC-1s by deacetylating lysine residues, thus leading to expression of PGC-1s target
genes [34]. Intriguingly, both GNC5 and Sirt1 act as energy sensors of the cell. When energy levels are
low, AMPK (AMP-activated protein kinase), by increasing NAD+ levels, promotes the deacetylase
activity of SIRT1, which results in PGC-1s activation and increased mitochondrial biogenesis and
function. Contrarily, in caloric excess conditions, GCN5 inhibits PGC-1s by acetylation, thus lowering
new mitochondria formation [35]. Thereby, via reversible acetylation/deacetylation of PGC-1s, Sirt1
and GNC5 give a tightly but flexible regulation of the mitochondrial synthesis in order to fulfil the
cellular energy demand.
Another level of complexity is introduced by additional PGC-1s post-translational modifications,
for instance phosphorylation and methylation as well as by the interaction with other proteins, such as
corepressors which alter PGC-1s stability and activity. PGC-1α could be phosphorylated directly by
three different kinases. p38 mitogen-activated protein (MAP) Kinase phosphorylates PGC-1α in its
repression domain, allowing a more stable and active protein [36,37]. AMPK could also phosphorylate
PGC-1α, leading to an increase of its target gene expression activity [38]. Notably, this phosphorylation
is required for the subsequent SIRT1-mediated deacetylation, thus suggesting a convergent biological
effect directed at increasing the specificity of PGC-1α activation [39].
By contrast with the aforementioned kinases, insulin-dependent activation of AKT (Protein
Kinase B) results in a more unstable PGC-1α protein, with a lower transcriptional activity [40]. Once
activated, AKT can exert both a direct and an indirect action on PGC-1α, the latter by phosphorylating
and stabilizing the Clk2 protein kinase. The Clk2-dependent phosphorylation of PGC-1α blunts its
coactivator activity leading to decreased glucose production due to the repression of gluconeogenesis
program [41].
Additionally, GSK3β (glycogen synthase kinase 3β) can phosphorylate PGC-1α in order to
promote its intranuclear proteasomal degradation during transient conditions of oxidative stress.
However, a chronic stress signal overcomes the GSK3β-mediated degradation, thus resulting in the
increased PGC-1α expression [42]. Furthermore, PGC-1α is a target of PRMT1 (protein arginine
N-methyltransferase 1). PRMT1 methylates PGC-1α on three arginine residues in the C-terminus,
hence promoting its activation [43].
By contrast with PGC-1α, PGC-1β post-translational modifications have been poorly studied.
It has been observed that SYVN1 (Synoviolin), an E3 ubiquitin ligase, ubiquitinates PGC-1β and,
consistently, SYVN1 deficient mice displayed decreased body weight and upregulation of PGC-1β and
of its target genes regulating mitochondrial biogenesis and function [44]. Overall, it is plausible that
PGC-1β acts in multiple protein complexes whose composition might depend on the specific target
genes as well as on the composition of different metabolic signals.
2.2. MicroRNA
MicroRNAs (miRNAs) are small non-coding RNAs, widely involved in the regulation of biological
processes, such as proliferation, development and energy metabolism. Firstly described in 1993,
microRNAs are small noncoding RNAs, about 22 nucleotides long that can finely tune gene expression,
either reducing transcript levels or interfering with protein translation [45–47]. Therefore, the discovery
of microRNAs deepens our knowledge on the post-transcriptional modifications of gene expression
and on how this process can regulate metabolic homeostasis and diseases development.
Genes that encode miRNAs are firstly transcribed by RNA polymerase II from DNA into an initial
hairpin transcript, called pre-miRNA, via either a canonical pathway, in which they are cropped by
the Drosha-DGCR8 complex, or via the Mirtrons pathway. Pre-miRNA are then exported into the
cytoplasm, where they are processed by Dicer into a mature, single stranded miRNA. Finally, miRNAs
are loaded onto the RNA-induced silencing complex (RISC) and guided to their mRNA targets through
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interactions with members of the Argonaute family. The unique complementarities between miRNA
and mRNA could reduce or increase the levels of a gene product [48].
The generation of mature miRNAs can be controlled both at transcriptional and posttranscriptional
level, and any alteration occurring in their synthesis leads to abnormal physiological and developmental
processes that can eventually contribute to disease onset [49–51].
In the liver, the distribution and function of some miRNAs is cell-specific and their dysregulation
has been associated with hepatic dysfunctions, to the point that extracellular circulating microRNAs
released from injured liver could be used as biomarkers of liver disease [5,51]. Hepatic miRNAs
can affect glucose and lipid homeostasis, inflammatory programmes as well as cell proliferation
and apoptosis. For instance, miR-122, an abundant liver microRNA which accounts for 70% of
liver total miRNA, regulates cholesterol biosynthesis and lipid metabolism [52,53]. Low levels of
miR-122 are found in non alcholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC),
in concomitance with inflammatory infiltrates producing pro-tumorigenic cytokines [54,55]. Mice
with total body miR-122 ablation are viable, but present an altered lipid metabolism that results
in steatohepatitis, fibrosis and liver cancer development [56]. On the contrary, miR-122 delivery
in MYC proto-oncogene, bHLH transcription factor (MYC)-driven HCC mouse model contributes
to tumorigenesis inhibition [55]. Finally, increased levels of circulating miR-122 are observed in
association with liver injury, thus sustaining the idea that specific microRNAs can be used as markers
of liver damage and inflammation [57].
New evidences indicate that, besides ‘canonical’ role of miRNAs in inhibition of target gene
expression, microRNAs could exert more complex and different roles. MiRNA can reduce or increase
mRNA expression via mRNA deadenylation, translational repression or activation, or other not
yet defined mechanisms [51]. Although more studies are required in order to understand the vast
complexity of miRNAs regulation, it is now clear that microRNAs participate to the maintenance
of the whole-body metabolic homeostasis, and alteration of their expression could not only directly
or indirectly modulate tissue metabolism, but can also favour the onset of diseases. In this view,
being aware of the genes and relative pathways regulated by microRNAs, but also of the transcriptional
factors or coregulators that modulate miRNAs expression is of fundamental importance.
2.2.1. Regulation of PGC-1s by MicroRNAs
The study of microRNAs offers an additional level of complexity on the modulation of
transcriptional coactivators activity. Until now, numerous analyses have revealed that different
microRNAs can directly control the expression of PGC-1s, thereby having an effect on whole body
metabolic homeostasis.
In an elegant study, Maniyadath et al. showed that hepatic-fed microRNAs exert a network-level
control over fasting genes to regulate metabolic and mitochondrial pathways, thus avoiding futile
cycles [4]. In particular, let7i, miR-221 and miR-222 are the most abundant microRNAs in re-fed
liver that are able to act in a convergent and additive way to control gluconeogenesis, fatty
acid oxidation and mitochondrial biogenesis by directly targeting PGC-1α [4]. The loss of these
microRNAs resulted in the failure to inhibit the expression of PGC-1α and downstream genes, thus
contributing to the onset of metabolic dysfunction and liver disease. The downregulation of PGC-1α
by miR-19b/221/222 has also been observed in human atherosclerotic vessels, where the coactivator
plays a protective role against vascular complications [58]. Likewise, estrogen deficiency leads to
diminished PGC-1α expression that results in the formation of compromised mitochondria, eventually
leading to enhanced cardiovascular risk in age-related ventricular concentric remodelling. In particular,
estrogen negatively regulates miR-23a which could directly bind PGC-1α, thus turning down its
expression [59]. It has been also observed in hepatocellular carcinoma that miR-23a can lessen
gluconeogenesis programs via direct binding at 3′UTR of both glucose 6-phosphatase and PGC-1α [60].
Similarly, adenoviruses-mediated overexpression of miR-29a-c in primary hepatocytes and mouse
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liver downregulates PGC-1α, thus contributing to the attenuation of hepatic glucose production and
alleviation of hyperglycemia [61].
Moreover, even miR-696 can regulate PGC-1α expression. This microRNA is downregulated
in the gastrocnemius during exercise and in the liver of genetically obese mice (ob/ob). Therefore,
by decreasing PGC-1α levels, miR-696 contributes to the regulation of muscle mitochondrial biogenesis,
hepatic gluconeogenesis and insulin resistance [62,63].
Finally, different studies indicated that miR-34a can directly target PGC-1α in hepatic and adipose
tissue. MiR-34a levels rise in the liver and in the white adipose tissue of high-fat diet (HFD) fed
mice. When miR-34a is knocked-out in mice using genetical or lentiviral approach, the PGC-1α
expression levels raise in liver and white adipose tissue [64–66]. Interestingly, activation of FXR
(farnesoid X receptor) by selective ligands decreases the expression of miR-34a, which in turn it is
not able to downregulate SIRT1, thus leading to enhanced PGC-1α activity [64]. However, despite
the marked elevation of the coactivator, the consequences of this miR-34-KO are different between
the two mouse models, probably due to the approaches used to shut-down the microRNA. Indeed,
the whole-body ablation of miR-34a leads to an increased body weight due to the production of
dysfunctional mitochondria that promote lipid uptake and storage, thus resulting in the accumulation
of inflammatory markers [66]. On the contrary, lentiviral-mediated transient downregulation of
miR-34a reduces adiposity and enhances mitochondrial copy number as well as oxidative capacity in
mice fed with diet-induced obesity [65]. Notably, it has been shown that full body PGC-1α knock out
mice are lean, but display defective mitochondrial functions [67].
Fewer studies have been published on the microRNA-mediated regulation of PGC-1β. Oleanolic
acid, an active component of the traditional Chinese herb Olea europaea L., induces the expression of
miR-98-5p which directly targets the 3′UTR of PGC-1β and promotes its mRNA degradation. Mice fed
with HFD supplemented with oleanolic acid display ameliorated hyperlipidaemia associated with
decreased PGC-1β levels, and treatment with miR-98-5p inhibitors reverses this effect [68]. Similarly,
in the goat mammary gland tissue, the overexpression of miR-25 represses PGC-1β expression and,
consequently, decreases triacylglycerol and lipid accumulation [69].
Generally, these studies highlight that also microRNA contribute to the well calibrated action of
both PGC-1α and PGC-1β on metabolic programmes in order to guarantee the whole-body homeostasis.
2.2.2. Regulation of MicroRNAs by PGC-1s
Hepatic microRNAs are involved not only in the maintenance of normal liver functions, but also
in liver diseases and cancer. Despite a large number of studies demonstrating that different microRNAs
control PGC-1s expression, to date the researches about the regulation of microRNAs expression by
PGC-1s are almost missing.
Notably, two microRNAs are embedded in the first intron of the PGC-1β gene, miR-378 and
miR-378*, which originate from a common hairpin RNA precursor [70]. Selective deletion of these
miRNAs in mice, leaving the PGC-1β gene intact, resulted in protection against diet-induced obesity.
Overall, miR-378 and miR-378* counterbalance the metabolic actions of PGC-1β by controlling the
oxidative capacity and the fatty acid metabolism [71].
Here, we report the data of a miRNAs microarray analysis on hepatic samples collected from fasted
transgenic mice in which the coactivators PGC-1α or PGC-1β have been specifically overexpressed in
the liver, namely LivPGC-1α and LivPGC-1β, respectively. The two differential microarray analyses
versus wild type mice have been carried out for LivPGC-1α mice (Figure 1) and for LivPGC-1β mice
(Figure 2). The most significative miRNAs differences emerging from each analysis have been then
validated by real-time quantitative polymerase chain reaction (qPCR) (Figure 3) that allowed the
comparison of the microRNA expression levels also between the two coactivators. Notably, the genomic
location of most of these miRNAs is inside or closed to genes regulated by PGC-1s or closely associated
to PGC-1′s activity (Table 1). Therefore, it is plausible that the expression of these microRNAs represents
a continuum of the gene regulation committed by PGC-1s. Intriguingly, for most of these microRNAs
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few literature data are available. Therefore, it will be interesting to explore if they are implicated in the
regulation of hepatic metabolic processes or in liver diseases (Figure 4).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 7 of 19 
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as relative expression values, and plotted as means ± standard error of the mean (SEM). Comparison of
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Table 1. Genomic characterization of microRNA upregulated by Pgc-1s. Abbreviations: Nfyc, nuclear 
transcription factor Y subunit gamma; Atp5b, ATP synthase F1 subunit beta; Yy1, Yin Yang 1; Elovl3, 
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interacting protein; Prmt1, protein arginine methyltransferase 1; PPARα, peroxisome proliferator-
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miRNA Sequence Location Proximal Gene Association with Pgc-1 
mmu-miR-30c-1 cugggagaggguuguuuacucc 
chr4: 120769534-
120769622 
Inside Nfyc gene 
Nfyc is a Pgc-1α target 
in striatal 
mmu-miR-677 uucagugaugauuagcuucuga 
chr10: 128085286-
128085363 
Inside Atp5b Atp5p is a Pgc-1s target 
mmu-miR-345-5p gcugaccccuaguccagugcuu 
chr12: 108836973-
108837068 
Downstream to Yy1 
Yy1 is regulated by and 
regulates Pgc-1s 
mmu-miR-345-3p ccugaacuaggggucuggagac 
chr12: 108836973-
108837068 
Downstream to Yy1 
Yy1 is regulated by and 
regulates Pgc-1s 
mmu-miR-146b ugagaacugaauuccauaggcu 
chr19: 46342762-
46342870 
Downstream to 
Elovl3 and Nfkb2 
Elovl3 is a PPARα 
target 
mmu-miR-34a uggcagugucuuagcugguugu 
chr4: 150068454-
150068555 
Downstream to 
Gm13067 
No information 
available 
mmu-miR-150 ucucccaacccuuguaccagug chr7: 45121757-45121821 
Downstream to 
Nosip and Prmt1 
Pgc-1s promote eNos 
expression, which in 
turn interact with 
Nosip. Prmt1 regulates 
Pgc-1s. 
Notably, miR-30c-1, miR-677 and miR-345-5p are significatively increased in LivPGC-1β mice 
with respect to the other two groups, whereas miR-146b and miR-34a are significatively upregulated 
in LivPGC-1β compared to wild type and LivPGC-1α respectively. Interestingly, miR-30c-1 and mir-
677 are enclosed into two genes whose expression is regulated by PGC-1s, i.e., nuclear transcription 
factor Y subunit gamma (Nfyc) and ATP synthase F1 subunit beta (Atp5b), respectively (Table 1). Mir-
677 has been found to be downregulated in the liver of female mice infected with Plasmodium chabaudi 
malaria and a concomitant upregulation of genes involved in the inflammatory pathway, as 
interleukin (IL)-1β, tumor necrosis factor-α (TNF-α) and nuclear factor κB (NF-κB), has been 
observed [72]. Anyway, if miR-677 can play any role in mitigating the inflammatory response has not 
yet been established. 
Mir-345-5p has been described in several types of cancer: in pancreatic ductal adenocarcinoma 
and in acute myeloid leukaemia miR-345-5p plays a tumor suppressive role, whereas in prostate 
Figure 4. MicroRNA target prediction and enrichment analysis of the predicted target genes.
The selective overexpression of PGC-1α or PGC-1β in the mice liver lead to the upregulation of
different microRNAs. Genes targeted by differentially expressed miRNAs were predicted using
TargetScan database. The gene set enrichment analysis was performed using EnrichR. The bar graphs
display the predicted mouse Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways based on
p-value ranking.
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Table 1. Genomic characterization of microRNA upregulated by Pgc-1s. Abbreviations: Nfyc,
nuclear transcription factor Y subunit gamma; Atp5b, ATP synthase F1 subunit beta; Yy1, Yin Yang
1; Elovl3, ELOVL fatty acid elongase 3; Nfkb2, nuclear factor kappa B subunit 2; Nosip, nitric
oxide synthase interacting protein; Prmt1, protein arginine methyltransferase 1; PPARα, peroxisome
proliferator-activated receptor alpha.
miRNA Sequence Location Proximal Gene Association with Pgc-1
mmu-miR-30c-1 cugggagaggguuguuuacucc chr4:120769534-120769622 Inside Nfyc gene
Nfyc is a Pgc-1α target in
striatal
mmu-miR-677 uucagugaugauuagcuucuga chr10:128085286-128085363 Inside Atp5b Atp5p is a Pgc-1s target
mmu-miR-345-5p gcugaccccuaguccagugcuu chr12:108836973-108837068 Downstream to Yy1
Yy1 is regulated by and
regulates Pgc-1s
mmu-miR-345-3p ccugaacuaggggucuggagac chr12:108836973-108837068 Downstream to Yy1
Yy1 is regulated by and
regulates Pgc-1s
mmu-miR-146b ugagaacugaauuccauaggcu chr19:46342762-46342870
Downstream to
Elovl3 and Nfkb2 Elovl3 is a PPARα target
mmu-miR-34a uggcagugucuuagcugguugu chr4:150068454-150068555
Downstream to
Gm13067 No information available
mmu-miR-150 ucucccaacccuuguaccagug chr7:45121757-45121821
Downstream to
Nosip and Prmt1
Pgc-1s promote eNos
expression, which in turn
interact with Nosip. Prmt1
regulates Pgc-1s.
Notably, miR-30c-1, miR-677 and miR-345-5p are significatively increased in LivPGC-1β mice
with respect to the other two groups, whereas miR-146b and miR-34a are significatively upregulated in
LivPGC-1β compared to wild type and LivPGC-1α respectively. Interestingly, miR-30c-1 and mir-677
are enclosed into two genes whose expression is regulated by PGC-1s, i.e., nuclear transcription factor
Y subunit gamma (Nfyc) and ATP synthase F1 subunit beta (Atp5b), respectively (Table 1). Mir-677 has
been found to be downregulated in the liver of female mice infected with Plasmodium chabaudi malaria
and a concomitant upregulation of genes involved in the inflammatory pathway, as interleukin (IL)-1β,
tumor necrosis factor-α (TNF-α) and nuclear factor κB (NF-κB), has been observed [72]. Anyway,
if miR-677 can play any role in mitigating the inflammatory response has not yet been established.
Mir-345-5p has been described in several types of cancer: in pancreatic ductal adenocarcinoma
and in acute myeloid leukaemia miR-345-5p plays a tumor suppressive role, whereas in prostate
cancer it promotes cell proliferation and migration by blocking p21, responsible for the inhibition
of cyclin-dependent kinases (CDK) CDK1 and CDK2 [73–75]. Moreover, in tissue and cell lines of
cholangiocarcinoma, the upregulation of the long non-coding RNA (lncRNA) AS1 sponges miR-345-5p,
thus removing the inhibition of collagen type VI alpha 3 (Col6A3), direct target of mir-345-5p, and
allowing tumor progression [76]. Contrariwise, the comparison between different datasets of cirrhosis
patients revealed that miR-345-5p expression, together with other four microRNAs, is associated with
increased levels of genes involved in liver fibrosis [77]. Finally, higher circulating levels of miR-345-5p
have been recently observed in children with early stage diabetes mellitus type 1 as compared with
age-matched controls [78].
In the liver, miR-146b has been widely correlated with inflammation in both NAFLD and
HCC [79]. MiR-146b is a negative regulator of toll-like receptor 4 (TLR4) and tumor necrosis factor
receptor-associated factor 6 (TRAF6) and its administration prevents liver injury in acute liver graft
injury in rats and ameliorates HFD-induced NAFLD in mice [80–82]. Analogously, decreased levels of
miR-146b have been detected in serum of NAFLD patients and in a mouse model of NAFLD induced
by methionine choline deficient diet [82,83]. Intriguingly, ablation of miR-146 in mice leads to severe
liver steatosis and hepatitis by the upregulation of TNF-α and IL-6 [82]. Conversely, elevated hepatic
level of miR-146b has been found in rats and mice treated with HFD as well as in obese subjects
with NAFLD [84–86]. Notably, the upregulation of miR-146b in obese individuals correlates with
a reduction of glucose metabolism and fatty acids mobilization [86]. In line with this observation,
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miR-146b inhibition in free fatty acids-treated primary hepatocytes displays a decreased accumulation
of cellular lipids [85]. Finally, miR-146 exerts a tumor suppressive role in liver cancer cells in vitro and
in vivo, through the inhibition of AKT activation mediated by TRAF6 [87].
Hepatic expression of miR-34a is also regulated by CREB-regulated transcriptional activator 2
(CRTC2) [88]. Although no evidence of interaction or association between CRTC2 and PGC-1β has
been so far reported, CRTC2 can positively regulate PGC-1α and downstream gluconeogenic genes in
the liver [89]. We have discussed above that miR-34a is able to inhibit PGC-1α translation. Therefore,
it seems that an intricate network between PGC-1s and miR-34a exists, probably in order to fine tune
the metabolic pathways of the cells. Additionally, also p53 directly targets miR-34a, which in turn
can activate p53 by downregulating SIRT1 action, thereby delineating a positive feedback loop. An
increased miR-34a/SIRT1/p53 activation has been observed in the hepatocytes of CCl4-induced rat liver
fibrosis, where it drives hepatocyte apoptosis, thus allowing the activation of hepatic stellate cells
and perpetuation of fibrosis [90]. Notably, by inhibiting SIRT1, miR-34a can affect the functioning of
a multitude of pathways. Indeed, increased miR-34a levels have been detected in liver of NAFLD
animals and morbid patients [91–94], while miR-34a inhibition resulted in active SIRT1 and increased
PPARα level, with concomitant restoration of triacylglycerol content and mitochondrial transmembrane
potential in mice liver [94,95]. Moreover, the downregulation of miR-34a resulted in a lower expression
of fibrotic genes upon alcohol-feeding in mice [96]. Indeed, miR-34a level is increased in the liver
of ethanol fed rats and mice as well as in heavy drinkers [96,97]. Furthermore, the downregulation
of SIRT1 induced by miR-34a leads to the activation of 3-hydroxy-3-methylglutaryl-CoA reductase
(HMGCR), which boosts new cholesterol synthesis, thus promoting high liver injury and cardiovascular
risk [92]. Interestingly, the ursodeoxicholic acid (UDCA), a secondary bile acid that contributes to
cholesterol homeostasis by reducing the rate of intestinal cholesterol absorption, blocks miR-34a activity
in the liver of NAFLD rats [91,98]. Moreover, in obesity conditions miR-34a attenuates fibroblast
growth factor 19 (FGF19) signalling, a key pathway in the regulation of bile acids synthesis [99].
Although a direct involvement of PGC-1β in cholesterol and bile acids pathways has not been reported
so far, it would be fascinating to explore this network in the light of the previously mentioned evidence.
Notably, it has been reported that PGC-1α activates cholesterol 7-alpha-hydroxylase (CYP7A1), the key
enzyme committed to the conversion of cholesterol into bile acids [100].
Despite the profibrotic role of miR-34a in NAFLD and alcoholic liver disease, several studies
reported a tumor suppressive role of miR-34a in HCC, even if none of them deeply investigated
miR-34a role in an in vivo cancer model [93,101,102].
Overall, PGC-1β overexpression leds to the upregulation of microRNAs that are extensively
involved in liver pathophysiology. If most of them exert an anti-fibrotic role by blocking inflammatory
pathways, others promote NAFLD and its sequelae. Notably, the PGC-1β overexpression in the
liver has been found to protect against NAFLD and NASH, whereas it supports tumor growth and
progression [103,104]. Therefore, it is possible that a fine tuning of these microRNAs upregulated in
LivPGC-1β mice exists and that further studies are mandatory to understand this intricate network.
miR345-3p is upregulated in both LivPGC-1α and LivPGC-1β mice compared to wild-type. To
date, no study focused on miR345-3p in the liver has been published. However, it has been observed
that this microRNA is decreased in non-small cell lung cancer and it is enriched in mitochondria from
failing heart at early stage [105,106]. Bioinformatic analysis revealed that the expression of miR-345-3p
is associated with energy metabolism and oxidative stress [105]. Given that both coactivators have a
similar effect on the induction of miR-345-3p, it would be interesting to understand if this microRNA
plays a role in the common pathways regulated by PGC-1s in the liver, namely, mitochondrial biogenesis
and/or antioxidant response.
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From our analysis, only one microRNA was increased in LivPGC-1α mice, i.e., miR-150. Of note,
this microRNA is located downstream of two genes whose expression products are known to interact
with PGC-1s, namely Nitric Oxide Synthase Interacting Protein (Nosip) and Prmt1 (Table 1). However,
to date no information regarding a direct regulation of these genes by PGC-1s has been described.
Whole-body miR-150 ablation in mice prevents Fas-induced apoptosis by regulating AKT, a direct target
of this miRNA [107]. Similarly, in HFD-induced NAFLD mice model and in NAFLD patients the levels
of miR-150 are increased and miR-150 deficiency ameliorates hepatic steatosis and insulin resistance
with concomitant reduction of fatty acids uptake and synthesis as well as of gluconeogenesis [108].
On the contrary, several works indicated that miR-150 inhibits Col4a4, Sp1 mediator of Col1a1,
and α-smooth muscle actin (α-SMA), therefore playing an anti-fibrotic role in the liver [109,110].
Intriguingly, endoplasmic reticulum stress induces the expression of the unfolded protein response
sensor IRE1α, which in turn mediates miR-150 degradation, thus enhancing liver fibrosis [109]. In line
with these data, miR-150 is repressed in HCC, and its re-expression in hepatoma cells suppresses cancer
cell proliferation, migration and invasion by blocking the matrix metalloproteinase 14 (MMP14) and
the GAB1/EK axis [111]. Overall, these data would fit with PGC-1α role in protecting the liver from
NAFLD, even if several controversies on the role of this coactivator on HCC still exist [18]. Probably,
new analyses taking into account miR-150 will provide further insights into this scenario.
3. Materials and Methods
3.1. Animals
LivPGC-1β transgenic mice were previously generated in our laboratory by Dr. E. Bellafante [103].
LivPGC-1α transgenic mice were generated by injecting into the pronuclei of the fertilized eggs of the
FVB/N mice the transgene digested with HpaI. To generate the pLiv.7 PGC-1α, first hPGC1α (2.4 kb)
fragment was generated by PCR from pcDNA4-His-PGC1α plasmid (Addgene, Watertown, MA, USA).
Then the fragment was subcloned KpnI and XhoI site of pLiv7 which carries the promoter, exon 1 and a
fragment of exon 2 of the Apolipoprotein E, a protein expressed exclusively in the liver. Mice carrying
the transgene were identified by PCR of genomic DNA to confirm the presence of an hPGC1α coding
sequence. LivPGC-1β and LivPGC-1α mice display hepatic-specific PGC-1β or PGC-1α overexpression,
respectively. We used wild-type (WT) FVB/N mice (referred as WT mice) as a control group. All mice
were housed with a standard diet provided ad libitum and examined daily. Genotyping was performed
using DNA extracted from tail biopsies of 4 weeks-old pups, and new breeding harems of 8 weeks-old
mice were established to expand the population. The ethics committee of the University of Bari
approved (1142/2016-PR and 509/2019-PR) this experimental setup, which was also certified by the
Italian Ministry of Health in accordance with internationally accepted guidelines for animal care.
3.2. RNA Samples Preparation
Tissues were snap frozen in liquid nitrogen and stored at −80 ◦C. Total RNA was isolated by
QIAzol reagent (Qiagen, Hilden, Germany) following the manufacture’s instruction, after tissue
homogenization through Qiagen TissueLyser (Qiagen, Hilden, Germany). To avoid possible DNA
contamination, RNA was treated with DNase (Thermo Fisher Scientific, Waltham, MA, USA). RNA
purity and concentration were checked by spectrophotometer, while the RNA integrity was assessed
by Bio-RadExperion™(Bio-Rad, Hercules, CA, USA). Only samples with Relative Quality Index (RQI)
> N8 were used for microarray analysis. Samples were stored in aliquot at −80 ◦C prior to use.
3.3. Microarray Analysis of miRNA Expression Profiles
Microarray gene expression analysis was performed on RNA extracted from the mice liver. Whole
RNA (400 ng) was studied using the Illumina Universal MicroRNA Expression Profiling (MicroRNA
Expression profiling kit and Illumina Universal Bead Chips (Illumina, San Diego, CA, USA)). The bead
chips were read on the Illumina iScan System microarray platform (San Diego, CA, USA). Upon
Int. J. Mol. Sci. 2019, 20, 5735 12 of 18
the manufacturer instructions, data were processed using the Illumina Genome Studio Software
(Illumina, San Diego, CA, USA) through specific algorithms of filtration and cleaning of the signal.
All the items with detection p value > 0.01 were excluded. Data were normalized together with the
quantile method. Background was not subtracted. Final output consisted of normalized fluorescence
intensity of each probe (Average signal), representing the expression levels of each miRNA. This
initial screening allowed us to identify 655 miRNAs to be exported from Genome Studio Software
on which, after transformation log2-transformed data, we thus performed the statistical analysis.
The identification of up- or down-regulated genes was performed by comparing miRNA expression
of transgenic mouse group versus wild type mice at basal condition. Prediction of miRNA targets
was performed using TargetScan [112]. The gene set enrichment analysis was performed using
EnrichR [113,114].
3.4. Reverse Transcription and Real-Time Quantitative Polymerase Chain Reaction (qPCR) for
miRNA Expression
For miRNA expression analysis, reverse transcription of 10 ng of RNA was performed using
TaqMan microRNA Reverse Transcription Kit (Thermo Fisher Scientific, MA, USA), following the
manufacturer’s instructions. Real-time qPCR assays were performed in 96-well optical reaction plates
using a Quantum5 machine (Thermo Fisher Scientific, MA, USA); qPCR assays were conducted in
triplicate wells for each sample, using pre-validated TaqMan Assays and TaqMan Universal Master
Mix (Thermo Fisher Scientific, MA, USA), according to the manufacturer instructions. Quantitative
normalization was performed using sno202 and sno234 as internal controls. Relative quantification
was done using the ∆∆CT method.
3.5. Statistical Analysis
The results are expressed as mean ± standard error of the mean (SEM). All the statistical analyses
were performed using GraphPad Prism software (v5.0; GraphPad Software Inc., San Diego, CA,
USA). Comparisons of three groups were performed using a one-way analysis of variance (Anova)
test followed by Tukey’s test for multiple comparison. At least p-value < 0.05 was considered
statistically significant.
4. Conclusions
PGC-1α and PGC-1β exert divergent functions on liver metabolism and regulate different
pathways in order to fulfil the cellular energetic demands and maintain whole-body homeostasis.
The post-transcriptional modulation of PGC-1s, either by post-translational modifications and by
microRNAs, allows a prompted response to both fed and fasted conditions. The failure of this regulation
results in disease onset and progression. On the other hand, PGC-1s’ overexpression is associated with
higher levels of several microRNAs involved in hepatic metabolic pathways, whose alteration may lead
to the initiation of liver steatosis, NAFLD and HCC. Here we reported initial insights into PGC-1-driven
regulation of miRNAs involved in liver metabolism, thus adding novel pieces in the puzzle of
modulation of liver energetic and potentially offering targets for future treatment development.
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